Literature DB >> 3052876

Alternative delivery systems for peptides and proteins as drugs.

D A Eppstein1, J P Longenecker.   

Abstract

The emergence of recombinant DNA technology has resulted in the large-scale production of a myriad of genetically engineered proteins and peptides, making many of them available for the first time for potential use as therapeutic entities. In addition, increased knowledge in the area of peptide/polypeptide hormones has resulted in an expansion of research efforts utilizing peptide synthetic chemistry, aimed toward developing novel therapeutic peptide drugs. Proteins and peptides cannot readily be administered by the conventional oral route, and thus alternative delivery methods to circumvent the necessity of frequent injections are being explored. This article reviews the current state-of-the-art technology of such methodologies, encompassing localized administration, administration to various body cavities (i.e., nasal, rectal, etc.), as well as controlled-release injectable or implantable systems. These different approaches result in quite different pharmacokinetics that may in part dictate which approach is best suited for a particular protein or peptide.

Mesh:

Substances:

Year:  1988        PMID: 3052876

Source DB:  PubMed          Journal:  Crit Rev Ther Drug Carrier Syst        ISSN: 0743-4863            Impact factor:   4.889


  11 in total

Review 1.  Drug delivery systems and routes of administration of peptide and protein drugs.

Authors:  L M Sanders
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1990 Apr-Jun       Impact factor: 2.441

Review 2.  Transport of peptide and protein drugs across biological membranes.

Authors:  J C Verhoef; H E Boddé; A G de Boer; J A Bouwstra; H E Junginger; F W Merkus; D D Breimer
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1990 Apr-Jun       Impact factor: 2.441

3.  Effects of absorption enhancers on human nasal tissue ciliary movement in vitro.

Authors:  W A Hermens; P M Hooymans; J C Verhoef; F W Merkus
Journal:  Pharm Res       Date:  1990-02       Impact factor: 4.200

4.  Nasal absorption enhancers for biosynthetic human growth hormone in rats.

Authors:  D T O'Hagan; H Critchley; N F Farraj; A N Fisher; B R Johansen; S S Davis; L Illum
Journal:  Pharm Res       Date:  1990-07       Impact factor: 4.200

5.  Biological effects of encapsulated insulin on transfected Chinese hamster ovary cells.

Authors:  M Roques; G Crémel; D Aunis; P Hubert
Journal:  Diabetologia       Date:  1995-02       Impact factor: 10.122

Review 6.  Intranasal insulin. Clinical pharmacokinetics.

Authors:  L Illum; S S Davis
Journal:  Clin Pharmacokinet       Date:  1992-07       Impact factor: 6.447

7.  Chitosan and chitosan/ethylene oxide-propylene oxide block copolymer nanoparticles as novel carriers for proteins and vaccines.

Authors:  P Calvo; C Remuñan-López; J L Vila-Jato; M J Alonso
Journal:  Pharm Res       Date:  1997-10       Impact factor: 4.200

8.  Inactivation kinetics of enzyme pharmaceuticals in aqueous solution.

Authors:  S Yoshioka; K Izutsu; Y Aso; Y Takeda
Journal:  Pharm Res       Date:  1991-04       Impact factor: 4.200

9.  Vaginal absorption of insulin in the rat: effect of penetration enhancers on insulin uptake and mucosal histology.

Authors:  J L Richardson; L Illum; N W Thomas
Journal:  Pharm Res       Date:  1992-07       Impact factor: 4.200

10.  Determinants of release rate of tetanus vaccine from polyester microspheres.

Authors:  M J Alonso; S Cohen; T G Park; R K Gupta; G R Siber; R Langer
Journal:  Pharm Res       Date:  1993-07       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.